Cyanine mitochondrial dye with slightly selective cytotoxicity against A549 cancerous cells.


Journal

Archiv der Pharmazie
ISSN: 1521-4184
Titre abrégé: Arch Pharm (Weinheim)
Pays: Germany
ID NLM: 0330167

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 01 08 2020
revised: 28 09 2020
accepted: 06 11 2020
pubmed: 28 11 2020
medline: 7 10 2021
entrez: 27 11 2020
Statut: ppublish

Résumé

Delocalized lipophilic cations (DLCs) are known as mitochondria-addressed molecules. Mitochondria targeting may provide opportunities for tumor detection. DLCs may have antioxidant or anticancer properties. In this study, we focused on the toxicity and localization of 2-[(E)-2-(5-fluoro-2-methyl-1H-indol-3-yl)ethenyl]-1,6-dimethylpyridin-1-ium iodide (62E2), which has recently been found as a novel cytotoxic fluorescent compound. The excitation maximum of 62E2 is 452 ± 10 nm and its emission maximum is 579 ± 10 nm. It is accumulated in the cells and stains mitochondria in nanomolar concentrations. 62E2 is cytotoxic and mitotoxic in low micromolar concentrations, and it demonstrates some selectivity of cytotoxicity against A549 cancer cells. The closest analog of 62E2 is F16, which is the fluorescent mitotoxic agent that has been described earlier as a potential anticancer agent. We hope that 62E2 described here is useful in expanding the diversity of cyanine fluorescent mitochondrial dyes and the analysis of their structure-activity relationships.

Identifiants

pubmed: 33245149
doi: 10.1002/ardp.202000281
doi:

Substances chimiques

Antineoplastic Agents 0
Fluorescent Dyes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2000281

Subventions

Organisme : Russian Foundation of Basic Research
ID : 18-29-08060
Organisme : Russian Science Foundation
ID : 17-74-30012

Informations de copyright

© 2020 Deutsche Pharmazeutische Gesellschaft.

Références

M. A. Kalinina, D. A. Skvortsov, M. P. Rubtsova, E. S. Komarova, O. A. Dontsova, Mol. Imaging Biol. 2018, 20(3), 368.
G. Battogtokh, Y. Y. Cho, J. Y. Lee, H. S. Lee, H. C. Kang, Front. Pharmacol. 2018, 9, 922.
J. S. Armstrong, Br. J. Pharmacol. 2007, 151(8), 1154.
L. A. Quayle, M. G. Pereira, G. Scheper, T. Wiltshire, R. E. Peake, I. Hussain, C. A. Rea, T. E. Bates, Oncotarget 2017, 8(51), 88670.
S. E. Weinberg, N. S. Chandel, Nat. Chem. Biol. 2015, 11(1), 9.
S. J. Ralph, P. Low, L. Dong, A. Lawen, J. Neuzil, Recent Pat. Anticancer Drug Discov. 2006, 1(3), 327.
S. Pustylnikov, F. Costabile, S. Beghi, A. Facciabene, Transl. Res. 2018, 202, 35.
J. Neuzil, L. F. Dong, J. Rohlena, J. Truksa, S. J. Ralph, Mitochondrion 2013, 13(3), 199.
H. Chen, J. Wang, X. Feng, M. Zhu, S. Hoffmann, A. Hsu, K. Qian, D. Huang, F. Zhao, W. Liu, H. Zhang, Z. Cheng, Chem. Sci. 2019, 10(34), 7946.
S. H. Dairkee, A. J. Hackett, Breast Cancer Res. Treat. 1991, 18(1), 57.
W. Xu, Z. Zeng, J. H. Jiang, Y. T. Chang, L. Yuan, Angew. Chem., Int. Ed. Engl. 2016, 55(44), 13658.
X. Liu, L. Yang, Q. Long, D. Weaver, G. Hajnoczky, Biophys. Rep. 2017, 3(4), 64.
A. Kholmukhamedov, J. M. Schwartz, J. J. Lemasters, Shock 2013, 39(6), 543.
R. C. Benson, H. A. Kues, J. Chem. Eng. Data 1977, 22(4), 379.
V. R. Fantin, M. J. Berardi, L. Scorrano, S. J. Korsmeyer, P. Leder, Cancer Cell 2002, 2(1), 29.
(a) K. Koya, Y. Li, H. Wang, T. Ukai, N. Tatsuta, M. Kawakami, Shishido, L. B. Chen, Cancer Res. 1996, 56(3), 538-543
(b) J. L.Chunta, K. S. Vistisen, Z. Yazdi, R. D. Braun, PLOS One 2012, 7(5), e37471.
H. Maruta, A. Tikoo, R. Shakri, T. Shishido, Ann. N. Y. Acad. Sci. 1999, 886, 283.
A. Tikoo, R. Shakri, L. Connolly, Y. Hirokawa, T. Shishido, B. Bowers, L. H. Ye, K. Kohama, R. J. Simpson, H. Maruta, Cancer J. 2000, 6(3), 162.
C. Brooks, Q. Wei, L. Feng, G. Dong, Y. Tao, L. Mei, Z. J. Xie, Z. Dong, Proc. Natl. Acad. Sci. U. S. A. 2007, 104(28), 11649.
E. J. Lawrence, E. Boucher, C. A. Mandato, Cell Div. 2016, 11. https://celldiv.biomedcentral.com/articles/10.1186/s13008-016-0015-4
J. Wang, H. He, C. Xiang, X. Y. Fan, L. Y. Yang, L. Yuan, F. L. Jiang, Y. Liu, Toxicol. Sci. 2018, 161(2), 431.
T. Mosmann, J. Immunol. Methods 1983, 65(1-2), 55.

Auteurs

Dmitry A Skvortsov (DA)

Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.
Ufa Scientific Centre, Institute of Biochemistry and Genetics Russian Academy of Science (IBG RAS), Ufa, Russia.

Sophia K Emashova (SK)

Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.

Marina A Kalinina (MA)

Skolkovo Institute of Science and Technology, Moscow, Russia.

Olga A Dontsova (OA)

Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.
Skolkovo Institute of Science and Technology, Moscow, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH